The Food and Drug Administration is providing final guidance on the pathway for “interchangeable” biologics, which may be substituted without the involvement of the prescriber.
Olopatadine hydrochloride ophthalmic solution, 0.2%, had a market value of $62 million for the 12 months ending December 2018, according to IQVIA data.